Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5052W HIGH $28.14
Volume
46.38 K
Value Traded
133.46 K
Short % Float
0.46%
-8.93%Week
-37.8%1 Month
-66.37%3 Month
-30.04%6 Month
-99.04%5 Year
-99.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.81 M
EPS (TTM)
-3.04
P/E Ratio
-
Ent. Value
8.63 M
Total Shares
1.84 M
Float Shares
2.01 M
Insiders
10.20%
Institutions
4.63%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
HCWB Catalyst Timeline
Dated clinical, regulatory and corporate events for HCW Biologics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for HCW Biologics Inc.
292Total events
21Upcoming
44Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of $1.5 million private placement with existing stockholder
▲Partnership / LicenseHCW11Corporate
HCW Biologics entered exclusive distribution agreement with Akron Biotech to commercialize HCW11-006 as a reagent for CAR-T production
▲Patent GrantedHCW9302IP / Competition
Notice of Allowance received from USPTO for claims directed to use of HCW9302 to treat alopecia areata
alopecia areatasource ↗
▲Interim Efficacy DataHCW9302Clinical Data
Preliminary readout of first two dose cohorts shows positive response after single dose at 3 micrograms/kg
alopecia areatasource ↗
●Enrollment UpdateHCW9302Trial
Treatment of patients in third dose cohort of HCW9302 underway
alopecia areatasource ↗
●Pre IND MeetingHCW11FDA Meeting
Requested Type B (pre-IND) meeting with FDA for HCW11-018b
solid tumorssource ↗
●Type B MeetingHCW11FDA Meeting
Type B (pre-IND) meeting requested with FDA for HCW11-018b
solid tumorssource ↗
◆Type B MeetingHCW11FDA Meeting
Requested Type B pre-IND meeting with FDA for HCW11-018b
solid tumors overexpressing human tissue factor, including gynecologic and pancreatic cancerssource ↗
▲Partnership / LicenseHCW11Corporate
Completed closing of exclusive worldwide licensing agreement with Beijing Trimmune Biotech for HCW11-006
▲Quarterly UpdateCorporate
Completed 28 consecutive trading days above $1.00 per share on June 25, 2026
●Quarterly UpdateCorporate
Filed amendments to Certificate of Incorporation with Delaware Secretary of State on June 24, 2026
▲Topline ReadoutHCW9302Clinical Data
Positive preliminary human data readout for first two dose cohorts of HCW9302 monotherapy in alopecia areata
alopecia areatasource ↗
◆Dose Finding UpdateHCW9302Trial
Dosing initiated in third dose escalation cohort (8 mcg/kg)
alopecia areatasource ↗
◆Enrollment UpdateHCW9302Trial
Patient enrollment on track; dosing initiated in third cohort
alopecia areatasource ↗
●Quarterly UpdateCorporate
Received decision letter from Nasdaq Hearings Panel on May 29, 2026
▲Partnership / LicenseHCW9206Corporate
Exercised option to regain full ex vivo rights to HCW9206 from Wugen
▲Partnership / LicenseHCW9201Corporate
Exercised option to regain full ex vivo rights to HCW9201 from Wugen
▼Equity OfferingCorporate
Pricing of approximately $4.0 million private placement offering at-the-market under Nasdaq rules
▲Partnership / LicenseHCW9206Corporate
Re-acquired ex vivo rights to HCW9206 from AlloTera Therapeutics
◆Management ChangeCorporate
Granted hearing to appeal Nasdaq delisting determination on May 5, 2026
◆Poster PresentationHCW11Presentation
Poster presented at AACR 2026 on HCW11-018b mechanism of action and anti-tumor activity
solid tumorssource ↗
▼Going ConcernCorporate
Substantial doubt about ability to continue as going concern for at least 12 months from March 31, 2026
▲Partnership / LicenseHCW11Corporate
Exclusive worldwide license for HCW11-006 closed with upfront fee received
▲Partnership / LicenseHCW11Corporate
Exclusive worldwide license for HCW11-006 with Beijing Trimmune closed on March 16, 2026
▲PublicationHCW9206Presentation
Publication of research on HCW9206-generated CAR-T cells in Science Advances
infectious diseases and cancersource ↗
▲Preclinical PoCHCW9206Preclinical
Preclinical proof-of-concept for HCW9206-generated CAR-T cells in HIV and leukemia models
HIV-1 and B-cell leukemiasource ↗
▲PublicationHCW11Presentation
Publication in Science Advances of preclinical data on HCW11-006-generated CAR-T cells
HIV-1 and B-cell leukemiasource ↗
▲Preclinical PoCHCW11Preclinical
Preclinical studies showed CAR-Ts manufactured using HCW11-006 were superior to standard methods
HIV-1 and B-cell leukemiasource ↗
▲First Patient DosedHCW9302Trial
First patient dosed in Phase 1 trial of HCW9302 for autoimmune disease
autoimmune diseasesource ↗
▲Partnership / LicenseHCW11Corporate
Exclusive worldwide license for HCW11-006 to Trimmune
solid tumorssource ↗
▲Partnership / LicenseHCW9302Corporate
Option to license exclusive Greater China rights for HCW9302
autoimmune disordersource ↗
▲Milestone PaymentHCW11Corporate
Upfront cash license fee payment of $3.5 million to HCW Biologics
◆Topline ReadoutHCW9302Clinical Data
Preliminary human data readout expected for HCW9302 Phase 1 trial
alopecia areatasource ↗
▼Going ConcernCorporate
Substantial doubt about going concern for at least 12 months from December 31, 2025
Past FDA Catalysts and PDUFA Decisions
How HCWB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F15 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 98%
Micro Cap(rank 645 of 658)
Percentile Rank
HCW Biologics Inc. has significant pipeline risk (15/100), with $39M risk-adjusted pipeline value, led by HCW9302 in Alopecia Areata(AA) (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HCW9302 Small moleculeNCT07049328 | Alopecia Areata(AA) | Phase 1 | RECRUITING | 30 | Dec 15, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every HCWB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HCW9302 | alopecia areata | Phase 1 | 2026-06-16 | all three participants showed preliminary indications of improvement in Severity of Alopecia Tool (SALT) scores; ≥25% reduction in SALT scores compared to baseline at four and/or nine weeks after dosingRead More | HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia AreataRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wong Hing CDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 23,210 125,845 held | $2.59 | 07/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HCWB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HCWB for Q2 2026. | ||||
HCWB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HCWB ranks across every disease it competes in
Competitive Position is a premium feature
See how HCWB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHCWB News
HCWB▲ +19.9%on this news
HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCW Biologics has announced the pricing of a $1.5 million private placement with an existing investor. The offering includes pre-funded warrants and common stock purchase warrants, pending stockholder approval. Proceeds will be used to advance clinical trials and other corporate purposes. Maxim Group LLC is the placement agent for this offering.
Read more →HCWB▼ -14.6%on this news
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics has entered an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine reagent aimed at enhancing CAR-T cell production. This partnership allows Akron to market HCW11-006 to its extensive network, potentially improving CAR-T therapies' efficacy and reducing production costs. Preclinical studies indicate that CAR-T cells produced with HCW11-006 exhibit superior functionality compared to traditional methods.
Read more →HCWBHCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW Biologics has received a Notice of Allowance for a patent on HCW9302, an IL-2-based immunotherapeutic for alopecia areata. The ongoing Phase 1 clinical trial is on track for completion in Q4 2026, with preliminary results indicating positive responses in patients. The company emphasizes strong intellectual property protection for HCW9302's development.
Read more →HCWB▲ +12.6%on this news· ran to +48% by day 3
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
HCW Biologics has introduced a novel TGF-β trap and IL-15 fusion that enhances immune cell activity against diseased cells and viral infections. Human studies indicate its effectiveness in expanding CD8+ T cells and NK cells, showing promise for cancer treatment. The company plans to advance its second-generation immunotherapeutics into clinical trials by 2027.
Read more →HCWBHCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics reported its second quarter 2026 highlights, showcasing promising preliminary data for HCW9302 in treating alopecia areata. The company is advancing in its Phase 1 clinical study without significant adverse effects. Financial results showed increased revenues but also a notable net loss, raising concerns about future sustainability. The company is actively pursuing partnerships and FDA discussions for its T-cell engager candidate, HCW11-018b.
Read more →HCWBHCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
HCW Biologics Inc. has announced a $1.6 million private placement offering, involving the issuance of 618,682 units to investors, including company executives. The offering will help fund clinical trials for its immunotherapeutic candidates. Stockholder approval is required for the issuance of Common Warrants, which may present some risks.
Read more →HCWB▼ -13.9%on this news· ran to -25% by day 1
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
HCW Biologics has requested a Type B pre-IND meeting with the U.S. FDA for its tetravalent T-cell engager, HCW11-018b, aimed at treating solid tumors. The investigational therapy has shown promise in preclinical studies, particularly for gynecologic and pancreatic cancers. The company also highlighted a streamlined manufacturing process that enhances production efficiency.
Read more →HCWB▼ -5.1%on this news
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
HCW Biologics Inc. has regained compliance with Nasdaq's Bid Price Rule as of June 29, 2026. The Nasdaq Hearings Panel confirmed this compliance, which is subject to monitoring until June 17, 2027. To maintain compliance, the company will execute a reverse stock split at a one-for-six ratio on June 30, 2026.
Read more →HCWB▼ -8%on this news· ran to -32% by day 3shared move
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
HCW Biologics has announced a 1-for-6 reverse stock split effective June 30, 2026, to comply with Nasdaq's Bid Price Rule. The company has successfully traded above the $1.00 threshold for 28 consecutive days as of June 25, 2026. This move is intended to maintain its listing on the Nasdaq Capital Market and will not affect stockholder ownership percentages.
Read more →HCWB▼ -6.6%on this news
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
HCW Biologics announced positive preliminary results from its Phase 1 clinical trial of HCW9302 for alopecia areata. All participants in the second dose cohort showed a significant reduction in Severity of Alopecia Tool scores. The treatment was well tolerated, with no serious adverse effects reported. The company aims to establish the recommended Phase 2 dose by the end of 2026.
Read more →HCWB▼ -26%on this news
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
HCW Biologics has regained full rights to two commercial-ready reagents, HCW9206 and HCW9201, from Wugen Inc. This move positions the company to leverage these compounds in the growing CAR-T immunotherapy market. HCW9206 shows promise in reducing production costs and enhancing therapeutic efficacy, potentially leading to improved patient outcomes in cancer treatments.
Read more →HCWB▲ +6.2%on this news· ran to -20% by day 3shared move
Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
HCW Biologics Inc. has priced a private placement of 2,846,975 units at $1.405 each, targeting to raise approximately $4.0 million. The proceeds will be used to advance clinical trials for their immunotherapeutic products including HCW9302 and HCW11-018b. Each unit comprises common stock or pre-funded warrants along with warrants for additional shares. The offering is expected to close around May 21, 2026, contingent on necessary regulatory approvals.
Read more →HCWBHCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
HCW Biologics announced that its investigational drug HCW11-040, a pembrolizumab-based fusion immunotherapeutic, has shown promise in preventing bronchopulmonary dysplasia (BPD) during IND-enabling studies. This rare pediatric disease affects underweight premature infants, causing severe long-term health issues. The company plans to file an IND application to evaluate HCW11-040 in high-risk patients and is encouraged by potential synergies with reauthorized rare pediatric disease programs. The positive results from studies in an animal model indicate a strong possibility for treating this unmet medical need among neonates.
Read more →HCWBHCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
HCW Biologics reported its first quarter 2026 results, highlighting significant revenue growth and ongoing clinical trials for HCW9302 in alopecia areata. The company successfully closed a licensing deal with Trimmune, generating $3.5 million in cash. However, concerns about its financial viability and potential Nasdaq delisting were noted, emphasizing the need for continued funding.
Read more →HCWB▲ +15.6%on this news
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
HCW Biologics announced the adjournment of its Special Meeting of Stockholders due to insufficient quorum. The proposals will be presented again at the Annual Meeting scheduled for June 15, 2026. The company is encouraging stockholders to vote on proposals related to warrants issued to Armistice Capital, which has invested $17.4 million in HCW Biologics.
Read more →HCWB▲ +16.9%on this newsshared move
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
HCW Biologics has announced significant advancements in its T-Cell Engager Program, specifically with its lead candidate HCW11-018b, which demonstrates strong anti-pancreatic cancer properties. The drug's mechanism of action was unveiled at the AACR Annual Meeting 2026, highlighting its ability to activate within the tumor microenvironment. An IND application is anticipated in the first half of 2027 for clinical trials.
Read more →HCWB▼ -16.7%on this news
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
HCW Biologics reported its fourth quarter and fiscal year 2025 results, highlighting the initiation of a first-in-human clinical trial for HCW9302, aimed at treating alopecia areata. The company received a significant upfront licensing fee for HCW11-006 and launched commercial-ready molecules. However, it faces financial challenges, including doubts about its ongoing viability and decreased revenues.
Read more →HCWB▼ -6.3%on this news· ran to -21% by day 3
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
HCW Biologics has finalized a $7 million exclusive license agreement for HCW11-006 with Beijing Trimmune Biotech. The deal includes a cash payment and equity interest, with Trimmune set to initiate a Phase 1 clinical trial in China in 2027. HCW Biologics retains the option to reclaim rights for the Americas post-trial.
Read more →HCWB▲ +81.2%on this newsshared move
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
HCW Biologics announced positive results for its proprietary compound HCW9206, which enhances the manufacturing of CAR-T cells for treating cancer and infectious diseases. Published in Science Advances, the research indicates that CAR-T cells produced with HCW9206 exhibit improved functionality and persistence compared to traditional methods. The findings suggest that employing HCW9206 may lead to more effective and cost-efficient immunotherapies, with potential applications in HIV treatment and leukemia. The study, led by a prominent team at Albert Einstein College of Medicine, highlights the compound's revolutionary approach to CAR-T therapy production.
Read more →About HCW Biologics Inc.
Headquarters2929 N COMMERCE PKWY, MIRAMAR, FL, 33025
BIOPHARMAWATCH ELITE PLUS
Trade the next HCWB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime